Targeting CD20+ Rituxan resistant B-cells with anti-CD3 activated T cells (ATC) armed with anti-CD3 x anti-CD20 (CD20Bi)

被引：0
|
作者：
Gall, JM
Grabert, RC
Deavers, M
Davoll, PA
Lum, LG
机构：
[1] Roger Williams Med Ctr, Providence, RI USA
[2] Boston Univ, Boston, MA 02215 USA
来源：
EXPERIMENTAL HEMATOLOGY | 2004年 / 32卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
19
引用
收藏
页码：35 / 35
页数：1
相关论文
共 50 条
  • [21] Naive T cells are resistant to anergy induction by anti-CD3 antibodies
    Andris, F
    Denanglaire, S
    de Mattia, F
    Urbain, J
    Leo, O
    JOURNAL OF IMMUNOLOGY, 2004, 173 (05): : 3201 - 3208
  • [22] Targeting advanced pancreatic cancer with activated t cells armed with anti-CD3 x anti-EGFR bispecific antibody.
    Lum, Lawrence G.
    Choi, Minsig
    Tri Minh Le
    Thakur, Archana
    Deol, Abhinav
    Ballen, Karen K.
    Volodin, Leonid
    Kindwall-Keller, Tamila L.
    Liu, Qin
    Dyson, Gregory
    Shields, Anthony Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer
    Garlie, NK
    LeFever, AV
    Siebenlist, RE
    Levine, BL
    June, CH
    Lum, LG
    JOURNAL OF IMMUNOTHERAPY, 1999, 22 (04): : 336 - 345
  • [24] b Relapsed and refractory malignant B cell diseases: Evidence for therapeutic efficacy via subcutaneous administration of anti-CD20 x anti-CD3 antibody lymphomun
    Buhmann, R.
    Ruf, P.
    Hess, J.
    Lindhofer, H.
    Jacob, U.
    Dreyling, M.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S505 - S505
  • [25] Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy
    Bannerji, Rajat
    Advani, Ranjana H.
    Brown, Jennifer R.
    Arnason, Jon E.
    Barnes, Jeffrey A.
    Allan, John N.
    Ansell, Stephen M.
    O'Brien, Susan M.
    Chavez, Julio C.
    Adriaens, Lieve
    Ufkin, Melanie
    Kostic, Ana
    Paccaly, Anne Josee
    Gao, Bo
    Lowy, Israel
    Sternberg, David
    Topp, Max S.
    BLOOD, 2017, 130
  • [26] Efficient Inhibition of Human B-cell Lymphoma in SCID Mice by Synergistic Antitumor Effect of Human 4-1BB Ligand/Anti-CD20 Fusion Proteins and Anti-CD3/Anti-CD20 Diabodies
    Liu, Rong
    Jiang, Wenguo
    Yang, Ming
    Guo, Hongxing
    Zhang, Yanjun
    Wang, Jinhong
    Zhu, Huifang
    Shi, Ruizan
    Fan, Dongmei
    Yang, Chunzheng
    Zhu, Zhenping
    Xie, Yong
    Xiong, Dongsheng
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (05) : 500 - 509
  • [27] Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation
    Yixin Li
    Roger J Kurlander
    Journal of Translational Medicine, 8
  • [28] ANTI-CD3 THERAPY INDUCES RAPID RENAISSANCE OF B220low B LYMPHOCYTES FOLLOWING B-CELL DEPLETION BY ANTI-CD20
    Wu, Gordon D.
    Klein, Andrew S.
    TRANSPLANT INTERNATIONAL, 2009, 22 : 15 - 15
  • [29] Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation
    Li, Yixin
    Kurlander, Roger J.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2010, 8
  • [30] SUPPRESSOR T-CELLS CAN BE ACTIVATED BY BIFUNCTIONAL ANTIBODY ANTI-CD3/CD8
    LI, Y
    MORAN, T
    TUTT, A
    MAYER, L
    FASEB JOURNAL, 1994, 8 (04): : A475 - A475
12345